Clinical Research Directory
Browse clinical research sites, groups, and studies.
Telacebec (T) Treatment in Adults With Buruli Ulcer (BU). (TREAT BU)
Sponsor: Barwon Health
Summary
The goal of this interventional clinical trial is to demonstrate the complete BU lesion healing rate by 52 weeks after treatment initiation, without relapse and/or curative intent excision surgery, after 10-28 days of telacebec (T) treatment. Males and females age 18 and older will be included. • Participants will attend visits every 2 weeks during treatment and thereafter every 2 weeks until week 24 Thereafter they will be followed by visits at weeks 30, 40, and 52. From week 10 to week 52, if the lesion has healed, follow-up visits may be remote.
Official title: A Phase 2 Multicentre, Open-label Study to Evaluate the Efficacy, Safety and Tolerability, and Pharmacokinetics of 14 -28 Days Telacebec Treatment in Adult Participants With Buruli Ulcer.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2024-07-09
Completion Date
2028-01
Last Updated
2026-06-30
Healthy Volunteers
No
Conditions
Interventions
Telacebec
The test product will be supplied as Telacebec 100mg tablets.
Locations (2)
Barwon Health
Geelong, Victoria, Australia
Royal Melbourne Hospital
Melbourne, Australia